---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055630"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T11:57:25.606078+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Olema reports Q1 net loss of $31.0M; cash $249M; enrollment complete in two palazestrant combo studies

## Summary
- Net loss of $31.0M for Q1 2024 vs $28.3M a year ago; cash & equivalents $249.0M.
- GAAP R&D expenses $29.9M, including $5.0M milestone to Aurigene for KAT6 program.
- Completed enrollment in 60-patient Phase 1b/2 studies of palazestrant + ribociclib and + palbociclib.
- New clinical data for palazestrant+ribociclib at ESMO Breast Cancer May 15-17; investor call May 15.
- Expect IND for OP-3136 (KAT6 inhibitor) in late 2024; plan Phase 1b/2 palazestrant+everolimus in Q3 2024.

## SEC filing metadata
- accession: 0000950170-24-055630
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000095017024055630/0000950170-24-055630-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000095017024055630/olma-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055630
- JSON: https://secwatch.observer/filing/0000950170-24-055630.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055630.txt

## Key facts
- Earnings Releases
  Olema Pharmaceuticals, Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $31.0 million.
  - Period: first quarter ended March 31, 2024
  - Net income: Net loss for the quarter ended March 31, 2024, was $31.0 million
  - Result: reported results
  source text: On May 8, 2024, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750284/000095017024055630/0000950170-24-055630-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.